Guide

Biosimilars pipeline report: A guide for understanding the growing market 

To date, there have been 59 approvals and 41 launches in the U.S. biosimilars market. 
Biosimilars are a promising product category, one that can provide patients and doctors with more affordable treatment options. As this market matures, its pipeline continues to grow. This reference guide is a useful tool to visualize and understand the current product landscape and potential future of this emerging market.

To view and read this report, please fill out the form. 

Related resources

White paper

Mastering the complexities of targeted medicines

Article

Addressing market access challenges as CGTs expand to larger patient populations

Webinar

How to turn poor TMF quality into TMF operational excellence

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.